Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Bacteria or actinomycetales
Reexamination Certificate
2002-10-02
2010-02-16
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Bacteria or actinomycetales
C424S001110, C424S078010, C424S093100, C424S093300, C424S093400, C424S184100, C424S234100, C424S278100, C435S252900
Reexamination Certificate
active
07662371
ABSTRACT:
The present invention describes a pharmaceutical, veterinary or alimentary composition comprising one or more bacterial strains capable of lowering the concentration of intestinal pathogenic peptides by means of peptidases of probiotic strains. The invention also relates to the use of such compositions, and a method for selection of probiotic strains. Also, the invention relates to novel bacterial strains.
REFERENCES:
patent: 4879213 (1989-11-01), Fox et al.
patent: 5310555 (1994-05-01), Zimmer
patent: 5494664 (1996-02-01), Brassart et al.
patent: 5709857 (1998-01-01), Morelli et al.
patent: 6022568 (2000-02-01), Lesens et al.
patent: 0 626 452 (1994-11-01), None
patent: 0969015 (2000-01-01), None
patent: WO 96/41879 (1996-12-01), None
Fernandes et al. 1987. FEMS Microbiology Review. vol. 46: 343-356.
Bernheimer et al., “Nature and Mechanism of Action of the Camp Protein of Group BStreptococci”, Infection and Immunity23(3): 838-844 (1979).
Burgess et al.,J. Cell Biol.111: 2129-2138 (1990).
Christie et al., “A Note on a Lytic Phenomenon Shown by Group BStreptococci”, Aus. J. Exp. Bio. Med. Sci.22: 197-200 (1944).
Fehrenbach et al., “Interaction of Amphiphilic Bacterial Polypeptides With Artificial Membranes”,Bacterial Protein Tokins, pp. 317-324 (1984).
Fehrenbach et al., Role of Camp-Factor (Protein B) for Virulence, (eds.)Bacterial Protein Toxins, Zbl. Bakt. Suppl.17: 351-357 (1988).
Finch et al,, “Further Studies on the Efficacy of a Live Vaccine Against Mastitis Caused byStreptococcus uberis”, Vaccine. 15(10): 1138-1143, 1997.
Figura et al., “Differentiation of Motile and Mesophilic Aeromonas Strains Into Species by Testing for a Campo-Like Factor”,J. Clin. Microbiol.25(7): 1341-1342 (1987).
Fontaine et al., “Immunisation of Dairy Cattle With RecombinantStreptococcus uberisGAPC or a Chimeric Camp Antigen Confers Protection Against Heterologous Bacterial Challenge”, Vaccine ;20:2278-2286, 2002.
Fontaine at al.. “Immunisation of Dairy Cattle With RecombinantStrptococcus uberisGAPC or a Chimeric Camp Antigen Confers Protection Against Heterologous Bacterial Challenge”, Vaccine 20:3047-3048, 2002.
Fraser, Gordon. “Bacteriology: Haemolytic Activity ofCorynebacterium”, Nature189: 246- (1961).
Frey et al., “Cloning and Expression of a Cohemolysin, The Camp Factor ofActinobacillus pleuropneumoniae”, Infection & Immunity 57(7): 2050-2056(1989).
George et al., “Macromol Sequencing Synthesis”,Select Meth. Appl.Alan Liss Inc. (1988).
Herzog et al.,DNA and Cell Biology, 12(6): 465-471 (1993).
Jiang et al., “Cloning, Sequencing and Expression of The Camp Factor Gene ofStreptococcus uberis”, 20: 297-307 (1996).
Jurgens et al., “Purification and Characterization of Camp-Factor FromStreptococcus agalactiaeby Hydrophobic Interaction Chromatography and Chromatofocusing”,Journal of Chromatography, 348: 363-370 (1985).
Jurgens et al., “Unspecific Binding of Group BStreptococcal cocytoiysen(Camp Factor) to Immunoglobins and Its Possible Role in Pathogenicity”,Exp. Med.165: 720-732 (1987).
Kohler, W. “Camp-Like Phenomena of Vibrios”,Zentralbl. Bakteriol. Mikrobiol. Hyg. Ser. A270: 35-40 (1988).
Lazar et al.,Mol. Cell. Biol.8(3): 1247-1252 (1988).
Leigh et al., “Vaccination With the Plasminogen Activator FromStreptococcus uberisInduces an Inhibitory Response and Protects Against Experimental Infection in the Dairy Cow”, Vaccine 17:851-857,1997.
Levinson et al.,Examination&Board Review, Medical Microbiology&Immunologypp. 292-293 (1994).
Podbielski,Med. Microbiol. Immunol.183: 239-256 (1994).
Rocourt et al., “Notes;Listeria welshimeriSP. Nov, andListeria seeligeriSP. Nov.”International J. Syst. Bacteriol.33(4): 866-869 (1983).
Rudinger et al., “Peptide Hormones”,ed. Parsons University Park Press(1976).
Ruhlmann et al., “Complete Amino Acid Sequence of Protein B”,Fed. Of Europ. Biochem. Soc.235 (1,2): 262-266 (1988).
Sambrook et al., “Expression of Cloned Genes inE. coli”, Molecular Cloning, A Laboratory Manual, Chp. 17,CSH(1989).
Schneewind at al., “Cloning and Expression of the Camp Factor of Group BStreptococciinEscherichia coli”, Infection&Immunity56(8): 2174-2179 (1988).
Skalka et al., “Lethal Effect of Camp-Factor and Uberis-Factor-A New Finding About Diffusible Exosubstances ofStreptococcus agalactiaeandStreptococcus uberis”, Zentraibl. Bakteriol. Ser. A249:190-194 (1981).
Sterzik et al., “Interaction of the Camp-Factor fromS. agalactiaewith Artificial Membrances”,Bacterial Protein Toxins, pp. 195-196 (1984).
Sterzik et al., “Structure and Function of Camp Factor ofStreptococcus agalactiae”, Zentralbl. Bakteriol. Mikrobiol. Hyg. Abt. 1, 15: 101-108 (1985).
Williams,Lett. Appl. Microbiol.12(1): 23-28 (1991).
Meisel et al., “Bioactive peptides encrypted in milk proteins: proteolytic activation and thropho-functional properties,” Antonie van Leeuwenhoek 1999; 76: 207-215.
Sanz et al., “Purification and Characterization of an X-Prolyl-Dipeptidyl Peptidase fromLactobacillus sakei,” Applied and Environmental Microbiology 2001; 67: 1815-1820.
Brudnak, M.A., “Application of genomeceuticals to the molecular and immunological aspects of autism,” Medical Hypothesis 2001; 57(2): 186-191.
Cornell et al., “The effect of gliadin peptides on rat-liver lysosomes in relation to the pathogenesis of coeliac disease,” Clinica Chimica Acta 1973; 49: 181-188.
Sandine, W.E., “Roles ofLactobacillusin the Intestinal Tract,” Journal of Food Protection 1979; 42(3): 259-262.
Matar et al., “Beta-Casomorphin 4 from Milk Fermented by a Mutant ofLactobacillus helveticus,” Int. Dairy Journal 1996; 6: 383-397.
Fernandes et al., “Therapeutic role of dietary lactobacilli and lactobacillic fermented dairy products,” FEMS Microbiology Reviews 1987; 46: 343-356.
International Search Report for PCT Application No. PCT/NO02/00354.
Brønstad Gunnar O.
Reichelt Karl Ludwig
Slinde Erik
Aniedobe Christopher
Dobe Law Group, LLC
Hines Ja'Na
Navarro Mark
Neurozym Biotech AS
LandOfFree
Composition for lowering the concentration of intestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for lowering the concentration of intestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for lowering the concentration of intestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151472